A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib/+Paclitaxel vs Placebo+Paclitaxel as First-line Treatment for Patients With Locally Advanced (Inoperable) or Metastatic TNBC. (CAPItello-290)
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line
Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer
A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib +
Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with
Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple negative Breast
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.